Xuewen Ma
- Hematology top 10%
- Multiple Myeloma Research and Treatments 12
-
- CAR-T cell therapy research 4
- Peptidase Inhibition and Analysis 3
-
- Monoclonal and Polyclonal Antibodies Research 7
-
- Chronic Lymphocytic Leukemia Research 2
-
- Protein Degradation and Inhibitors 2
- Cancer therapeutics and mechanisms 1
-
- Synthesis and Biological Evaluation 2
- Co-authors
- Li DiEdward H. KernsGuy T. CarterYouping HuangBrandi HilderPaula Rodríguez‐OteroNiels W.C.J. van de DonkMaría‐Victoria Mateos
- Journals
- Journal of Clinical Oncology (3 papers)Blood (3 papers)Clinical Pharmacology & Therapeutics (2 papers)
- Partner nations
- United StatesSpainNetherlands
In The Last Decade
Xuewen Ma
11 papers receiving 221 citations
Peers
Comparison fields: 5 of 38
- Hematology 129
- Oncology 135
- Radiology, Nuclear Medicine and Imaging 75
- Pharmacology 18
- Immunology 40
Countries citing papers authored by Xuewen Ma
This map shows the geographic impact of Xuewen Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xuewen Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xuewen Ma more than expected).
Fields of papers citing papers by Xuewen Ma
This network shows the impact of papers produced by Xuewen Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xuewen Ma. The network helps show where Xuewen Ma may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xuewen Ma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2023 | 25 | |
| 4 | 2023 | 4 | |
| 5 | 2023 | 10 | |
| 6 | 2023 | 0 | |
| 7 | 2023 | 0 | |
| 8 | 2023 | 3 | |
| 9 | 2023 | 59 | |
| 10 | 2023 | 15 | |
| 11 | 2022 | 10 | |
| 12 | 2022 | 13 | |
| 13 | 2022 | 1 | |
| 14 | 2021 | 40 | |
| 15 | 2008 | 49 |
About Xuewen Ma
Xuewen Ma is a scholar working on Hematology, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 15 papers that have together received 230 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (12 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), CAR-T cell therapy research (4 papers), Peptidase Inhibition and Analysis (3 papers), Chronic Lymphocytic Leukemia Research (2 papers), Protein Degradation and Inhibitors (2 papers), Synthesis and Biological Evaluation (2 papers) and Cancer therapeutics and mechanisms (1 paper). The work is most often cited by research in Hematology (129 citations), Oncology (135 citations) and Radiology, Nuclear Medicine and Imaging (75 citations). Xuewen Ma has collaborated with scholars based in United States, Spain and Netherlands. Frequent co-authors include Li Di, Edward H. Kerns, Guy T. Carter, Youping Huang, Brandi Hilder, Paula Rodríguez‐Otero, Niels W.C.J. van de Donk, María‐Victoria Mateos, Jaszianne Tolbert and Christoph Heuck. Their work appears in journals such as Journal of Clinical Oncology, Blood and Clinical Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.